Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 14 · newest first

  1. Clinical characteristics of patients with relapsed multiple myelomaCancer Treatment Reviews · 2015
  2. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic reviewOncoTargets and Therapy · 2015
  3. An update on the use of lenalidomide for the treatment of multiple myelomaExpert Opinion on Pharmacotherapy · 2015
  4. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaHaematologica · 2015
  5. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaExpert Review of Anticancer Therapy · 2015
  6. Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine · 2015
  7. The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short reviewJournal of Solid Tumors · 2015
  8. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisalThe Breast · 2015
  9. Treatment options for relapsed and refractory multiple myelomaBlood · 2015
  10. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-pointHaematologica · 2015
  11. Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian CancerPLoS ONE · 2015
  12. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood · 2015
  13. Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering AnalysisPLoS ONE · 2015
  14. Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus StatementJournal of Clinical Oncology · 2015
  15. Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesAmerican Journal of Hematology · 2015
  16. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA studyAmerican Journal of Hematology · 2015
  17. Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple MyelomaEuropean Oncology & Haematology · 2015
  18. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine · 2014
  19. Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple MyelomaBlood · 2014
  20. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myelomaHaematologica · 2014
  21. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasoneBritish Journal of Haematology · 2014
  22. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myelomaBlood Cancer Journal · 2014
  23. A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myelomaAmerican Journal of Hematology · 2014
  24. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaHaematologica · 2014
  25. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine · 2014
  26. Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studiesLeukemia & lymphoma/Leukemia and lymphoma · 2014
  27. European Perspective on Multiple Myeloma Treatment Strategies in 2014The Oncologist · 2014
  28. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood · 2014
  29. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialBMC Cancer · 2014
  30. Female breast cancer in Europe: statistics, diagnosis and treatment modalities.2014
  31. Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.Journal of Clinical Oncology · 2014
  32. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patientsAmerican Journal of Hematology · 2014
  33. The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinomaBMC Cancer · 2014
  34. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myelomaBlood Cancer Journal · 2014
  35. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaLeukemia · 2014
  36. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaHaematologica · 2014
  37. Staging and prognostication of multiple myelomaExpert Review of Hematology · 2014
  38. Less strength and more fractures for MGUS bonesBlood · 2014
  39. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationJournal of Clinical Oncology · 2014
  40. Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma PatientsInternational Journal of Dentistry · 2014
  41. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agentsEuropean Journal Of Haematology · 2013
  42. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerCarcinogenesis · 2013
  43. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysisLeukemia & lymphoma/Leukemia and lymphoma · 2013
  44. Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)Blood · 2013
  45. The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome InhibitorsBlood · 2013
  46. Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)Blood · 2013
  47. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trialLeukemia & lymphoma/Leukemia and lymphoma · 2013
  48. Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study groupAmerican Journal of Hematology · 2013
  49. Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Blood · 2013
  50. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study groupAmerican Journal of Hematology · 2013